Active, not recruitingPhase 2NCT06524375
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genentech, Inc.
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Venetoclax(drug)
- Enrollment
- 118 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2030
Study locations (20)
- Highlands Oncology Group, Springdale, Arkansas, United States
- Rocky Mountain Cancer Centers (Aurora) - USOR, Aurora, Colorado, United States
- Cancer Specialists of North Florida, Jacksonville, Florida, United States
- Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne, Indiana, United States
- Mission Blood and Cancer - MercyOne Cancer Center, Des Moines, Iowa, United States
- American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
- Dana-Farber Cancer Institute - Hematologic Oncology Treatment Center, Boston, Massachusetts, United States
- Nebraska Cancer Specialists St Francis - Grand Island, Grand Island, Nebraska, United States
- Nebraska Cancer Specialists, Omaha, Nebraska, United States
- Astera Cancer Care East Brunswick, East Brunswick, New Jersey, United States
- San Juan Oncology Associates, PC, Farmington, New Mexico, United States
- Oncology Hematology Care Inc - Cincinnati - USOR, Cincinnati, Ohio, United States
- Ohio State University, Columbus, Ohio, United States
- Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
- Asante Rogue Regional Medical Center, Medford, Oregon, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06524375 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn